コンテンツへスキップ
Merck
  • Enhancing depression mechanisms in midbrain dopamine neurons achieves homeostatic resilience.

Enhancing depression mechanisms in midbrain dopamine neurons achieves homeostatic resilience.

Science (New York, N.Y.) (2014-04-20)
Allyson K Friedman, Jessica J Walsh, Barbara Juarez, Stacy M Ku, Dipesh Chaudhury, Jing Wang, Xianting Li, David M Dietz, Nina Pan, Vincent F Vialou, Rachael L Neve, Zhenyu Yue, Ming-Hu Han
要旨

Typical therapies try to reverse pathogenic mechanisms. Here, we describe treatment effects achieved by enhancing depression-causing mechanisms in ventral tegmental area (VTA) dopamine (DA) neurons. In a social defeat stress model of depression, depressed (susceptible) mice display hyperactivity of VTA DA neurons, caused by an up-regulated hyperpolarization-activated current (I(h)). Mice resilient to social defeat stress, however, exhibit stable normal firing of these neurons. Unexpectedly, resilient mice had an even larger I(h), which was observed in parallel with increased potassium (K(+)) channel currents. Experimentally further enhancing Ih or optogenetically increasing the hyperactivity of VTA DA neurons in susceptible mice completely reversed depression-related behaviors, an antidepressant effect achieved through resilience-like, projection-specific homeostatic plasticity. These results indicate a potential therapeutic path of promoting natural resilience for depression treatment.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ラモトリジン, ≥98%, powder
Supelco
ラモトリギン 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
ラモトリジン, United States Pharmacopeia (USP) Reference Standard
Supelco
ラモトリジン, Pharmaceutical Secondary Standard; Certified Reference Material
ラモトリジン, European Pharmacopoeia (EP) Reference Standard
システム適合性用ラモトリジン, European Pharmacopoeia (EP) Reference Standard
ラモトリジン, European Pharmacopoeia (EP) Reference Standard